Extended-Release Niacin Lowers ApoB-48 Concentration in T2DM

This article originally appeared here.
Share this content:
ERN together with statin reduces apoB-48 by lowering fasting and postprandial secretion rate.
ERN together with statin reduces apoB-48 by lowering fasting and postprandial secretion rate.

(HealthDay News) -- For patients with type 2 diabetes, a statin plus extended-release niacin (ERN) lowers apolipoprotein B-48 (apoB-48) concentration compared to a statin alone, according to a study published online in Diabetes, Obesity and Metabolism.

Jing Pang, from the University of Western Australia in Perth, and colleagues examined the effect of ERN on apoB-48 kinetics in 12 statin-treated men with type 2 diabetes. Participants were randomly allocated to receive 12 weeks of rosuvastatin (R) or R plus ERN and then crossed over to the alternative treatment. At the end of each treatment period, postprandial metabolic studies were performed and apoB-48 kinetics were determined.

The researchers found that the apoB-48 concentration was lower with ERN versus statin alone (P = 0.03). ERN treatment also correlated with significantly lower postprandial triglyceride and apoB-48 area under the curve (AUC; P < 0.05), with no change seen in triglyceride and apoB-48 incremental AUC. ERN treatment was associated with lower apoB-48 secretion rate (SR) in the basal state (P = 0.04) and a lower number of apoB-48 containing particles secreted in response to fat load (P = 0.02). ERN was not associated with alteration in apoB-48 fractional catabolic rates (P = 0.79).

"ERN reduces apoB-48 concentration by lowering fasting and postprandial apoB-48 SR," the authors write. "This effect may be beneficial for lowering atherogenic postprandial lipoproteins and may provide cardiovascular disease risk benefit in patients with type 2 diabetes."

One author disclosed financial ties to Abbott, which provided the ERN for the study.


  1. Pang J, Chan DC, Hamilton SJ, Tenneti VS, Watts GF, and Barrett PHR. Effect of Niacin on Triglyceride-Rich Lipoprotein Apolipoprotein B-48 Kinetics in Statin-Treated Patients with Type 2 Diabetes. Diabetes Obes Metab. doi: 10.1111/dom.12622. 
You must be a registered member of Renal and Urology News to post a comment.

Newsletter Signup